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halamydia
are obligate intracellular parasites with
complexe reproductive cycle. The genus com-
prises four different species: C. trachomatis, C. pneu-
moniae, C. psittaci and C. pecorum. Most of the work
concerning the immune response is found on C.
trachomatis as it is a major public health problem
throughout the world. However the other species
are also of interest as C. psittaci is one of the most
important zoonose in the world and C. pneumoniae,
recently identified as a separate species, is a com-
mon cause of upper and lower respiratory infection
worldwide. The seroprevalence of this agent is rang-
ing between 40 and 70%. It has also been suggested
that C. pneumoniae may play a role in asthma and
in coronary disease.
In contrast to C. trachomatis, C. pneumoniae and
C. psittaci are able to infect different type of cells
such as alveolar macrophages, human monocytes
and endothelial cells. This explains the easy access
to different organs of the host and the presence of
chlamydia and their structural components into the
circulation. These components can bind to antibod-
ies present in the blood and form immune com-
plexes which maintain inflammatory reactions in
the vascular system.
Infections in untreated man and animals with C.
psittaci sometimes are very severe and may lead to
death underlying the importance of the acute phase
of these infections. One can notice that the exact
physiopathology of this death is not fully under-
stood. Is the endotoxin of C. psittaci far more aggres-
sive than the one found in C. trachomatis?
For those who recovered the questions of host
resistance and immunity arise. As underlined by
Storz33 to understand this problem of natural resis-
tance and acquired immunity one has to consider
the nature of these infectious agents as obligate
intracellular parasites and their possibility to re-
main latent.
Article
IMMUNITY FOLLOWING
NATURAL INFECTIONS
Immunity following chlamydiosis is difficult to
study but seems to be relative. Stram and Sery
reported relapse or reinfection in persons at risk.
In chlamydiosis ofbirds there is a different suscepti-
bility according to species and recovery from an
infection leads to immunity.
Stamp, et al.3z described an increased resistance
in ewes after chlamydial abortion. They generally
did not abort a second time. Mice developed resis-
tance to reinfection after an experimental infection.
Most of the knowledge acquired these last years
relied on experiments in mouse models and in
guinea pigs models.
MECHANISM OF NATURAL RESISTANCE
The local reaction to all chlamydial infections is
characterised by heavy infiltration with inflamma-
tory cells. During the acute phase polymorphs
(PMN) mostly neutrophils predominate within the
alveoli. In order to evaluate their role in combating
chlamydial infection, Register, et al. 29 examined the
effect that chlamydia and human PMN have on one
another in vitro. They showed that chlamydiae exert
a chemotactic effect on human PMN in the pres-
ence of complement suggesting activation of com-
plement. This phenomenon occurred with and
without specific anti chlamydia antibodies.
Studies on the uptake and intracellular fate of
chlamydia was devised to understand the role of this
interaction for the outcome of infection. As early
as 15 rain post inoculation approximately 65% of
the PMN-associated EB have been rendered non-
infectious probably after fusion of lysosomes with
chlamydia laden phagosomes and at least half of
the infective organisms are rapidly inactivated. It
is interesting to note that a small percentage of C.
psittaci are capable of remaining intact and infec-
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tious for a long period of time. They would be
capable of infecting macrophages or epithelial cells
once they are released from the dying PMN.
PMN infected with chlamydiae may be engulfed
by macrophages as shown by Newman et al. z4 Those
infectious EB may develop in the macrophage and
these cells may serve as a vehicle in the dissemina-
tion of C. psittaci infection.
Thus, as in other infectious diseases, PMN play
an ambiguous role both protective in killing EB
and deleterious in facilitating the spread of the in-
fectious EB. Here perhaps is one of the physiopath-
ological differences between C. psittaci and C. tra-
chomatis.
Chlamydia can induce interferon in the host. Dif-
ferent experiments have shown an association be-
tween induction of interferon in vitro and control
of the infection. In vitro, interferon can inhibit in-
clusion formation.
Another aspect of natural resistance is the control
of infection by genetic factors. In mice infected by
C. psittaci the evolution of the disease is different
according to different genotypes. C57BL/6 are
strongly resistant showing no symptoms of infection
even when massively inoculated whereas BALB/c
and DBA/2 are very sensitive. For them death oc-
curs within a few days after inoculation before any
installation of acquired immunity. Fuentes lz tried
to study the genetic basis of these different resist-
ances. For that, imbred recombinant C571B1
BALB/c (C B) were elaborated.
The first generation hybrids were resistant but
a curious phenomenon appeared: In spite of their
resistance the number of virulent particles in the
spleen of the F1 was as high as that found in the
sensitive parent. The dominance is thus linked to
the sensitivity. The back-cross mice with the resis-
tant parent developed a bimodal distribution char-
acteristic of a monogenic transmission suggesting 2
possibilities for the localisation of the responsible
gene on H 15 and H 30. It is noteworthy to stress
that this localisation is different from the one dem-
onstrated for BCG.
ACQUIRED IMMUNITY
Antibody Response
Chlamydia have a typical cell wall component lipo-
polysaccharide (LPS) which is highly antigenic and
different protein epitopes capable of inducing vari-
ous kind of antibodies. Animals and humans in-
fected with C. psittaci and C. pneumoniae show a high
level of anti LPS antibodies.
The antibody response of cows and ewes when
they are pregnant is characteristic. An initial mild
chlamydial antibody response occurs after intramus-
cular or subcutaneous inoculation. This response is
transient and the antibody titer become low or nul
before the termination of gestation. The length of
the seronegative period before abortion depends on
the time interval between inoculation and termina-
tion ofgestation. Ifby artificial mechanism the level
of antibodies remain high abortion does not occur.
It seems that in this special case antibodies play a
role in protection.
In other cases the role of antibodies remained
ill defined; Chlamydia-neutralizing antibodies were
demonstrated in pigeons and hyper-immunized
roostersz7 but these neutralizing antibodies are sel-
dom found in mammals after recovery ofchlamydial
infection. In the mouse model developed by Bu-
zoni-Gated passive transfer of monoclonal antibod-
ies protect pregnant mice against abortion and fetal
colonisation; placental colonisation was lowered by
5 Lg plaque forming unit. This emphasized the
necessity of defining the correct epitope in order
to develop protective antibodies. De Sa in the same
lab showed the protective ability of a preparation
containing native oligomeric MOMP associated
with an adjuvant, the LPS of S. typhimuriumRE.
In other experimental models when C. psittaci is
inoculated IV the transfer of antibodies does not
protect at all.
Thus even if antibodies may have some neu-
tralising effect on the adhesion phase of infectious
EB other mechanisms must be investigated.
An interesting approach to the antibody response
was made by Westbay et al.35 who demonstrated
that the LPS of chlamydia is a selective factor for
the appearance of specific immunoglobulin iso-
types. They compared the isotype of antibodies
specific for the cysteine-rich outer membrane pro-
tein omp2 induced in normal and in LPS hypore-
sponsive mice. The predominantly IgG2a isotype
in LPS hyporesponsive mice is replaced by a high
level of IgG1 in LPS responder strains.
This is linked to the structure of the antigen and
its natural processing pathway. These results may
be of interest when one considers the protective
efficacy of the different classes of antibodies.
All chlamydial species have a tendency to cause
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chronic infections. Persistent C. psittaci infections
in birds and mammals have been known for years
and infections caused by LGV and C. psittaci may
persist in humans for 10-20 years.
Furthermore, as in the case of C. pneumoniae,
infected alveolar macrophages or endothelial cells
are in close contact with the circulation. By demon-
strating the presence of chlamydial LPS-containing
immune complexes in diseases associated with pos-
sible chronic chlamydial infections like acute myo-
cardial infarction and chronic coronary heart dis-
ease19,zl,3 it has been confirmed that chlamydial LPS
undoubtedly has an access to the circulation. How-
ever, shock-like symptoms have never been de-
scribed in connection with chlamydial infections
but these long-lasting anti-LPS antibodies may play
a deleterious role.
Heat shock (or stress) proteins have important
functions in cellular metabolism and they aid cells
in dealing with environmental stimuli,z They are
highly conserved and exhibit wide cross-reactivity
among eucaryotic cells, parasites and bacteria. 37,38
During acute and chronic infections caused by para-
sites and bacteria, antibodies to heat shock proteins
are produced and these may act as "autoimmune"
antibodies and lead to tissue injury. Recent studies
have shown that Chlamydia possesses at least two
heat shock proteins, a 57 kD protein belonging to
the 60 hsp family and a 70kD protein belonging to
the 70 hsp family.’8,zz
Sera from patients with C. pneumoniae infection
in the USA have been reported to contain antibod-
ies most frequently towards a high molecular weight
98 kDa protein which has been considered C. pneu-
moniae specific, while in chronic infections antibod-
ies frequently recognise 43 kDa and 52 kDa pro-
teins, z8 Two of these proteins, the 98 kDa and 43
kDa proteins, are also recognized by immune com-
plex-bound antibodies in the sera of Finnish pa-
tients with chronic coronary heart disease.
Since antibodies are lost after an acute infectionz6
and the prevalence rises steadily, it can be esti-
mated that the majority of people have 2 or 3 C.
pneumoniae infections during their lifetime and evi-
dently primary infection does not protect from rein-
fections.
The hypothesis concerning the role ofheat shock
proteins in the pathogenesis of chlamydial infec-
tions, first suggested by Morrison, et al. z3 and Bavoil,
et al. is the following: chlamydial infections are
usually limited anatomically and temporally by po-
tent cell mediated and humoral immune responses.
After the primary infection, hypersensitivity reac-
tions with tissue injury can occur upon re-exposure
to the organism, such as in trachoma. During this
phase organisms are rarely isolated, but inflamma-
tory symptoms are strong. Recent data on the role
of mycobacterial stress proteins and auto-reactive
T-lymphocytes suggest autoimmune mechanisms
in the pathogenesis of chronic mycobacterial dis-
ease. These mechanisms might also play a role in
the immunopathologic sequelae of chronic chla-
mydial infections.
Cell Mediated Immune Response
T cell mediated immunity is reported to be im-
portant in the defense against intracellular patho-
gens. Drobyshevskaya, et al.1 as early as 1962,
studying normal and immunized mice inoculated
intranasaly by CE, demonstrated a marked quanti-
tative difference between the two groups in the
dynamics of multiplication of the chlamydia with a
lower titer in the immunized group. In contrast
to control mice chlamydial multiplication in the
macrophages of vaccinated mice was limited and a
larger proportion of infected cells remained viable.
Macrophages and large round cells appeared in the
lungs of immunized mice concentrated around
blood vessels forming dense cellular cuffs. Lympho-
cytes and histiocytic cells with mitotic figures were
present in these perivascular aggregates of immu-
nized mice.
This early work stresses the importance of mac-
rophages and lymphocytes. Many different experi-
ments were subsequently performed in order to
analyse the different organisms involved.
Chlamydia psittaci (Cp) avian strain Loth (Loth)
has been shown to be very pathogenic for different
strains of mice: DBA/2, C3H/He and BALB/c. For
these mice, the inoculation of Loth strain results
in the death of animals in 3 to 10 days. The same
effect is observed with the 6BC strain of Cp. With
this strain, the intraperitoneal inoculation of a single
elementary body is lethal for sensitive mice. Byrne
showed that BALB/c mice can be protected with a
sublethal intramuscular inoculation with the 6BC
strain.
However immunity can be demonstrated using
another less virulent strain the ovine abortion strain
A/22. zz BALB/c mice inoculated with this A/22 strain
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remain perfectly healthy and are protected when
reinoculated with the lethal Loth strain. This model
can be used to elucidate the mechanisms involved
in this crossed immunity.
Survival of Loth-inoculated mice was considered
as definitive after 3 weeks post-Loth inoculation.
For transfers experiments, mononuclear spleen
cells were first purified by Ficoll/Paque density
Gradient and further selected using CD4 or CD8
enrichment columns. Production of cytokines and
inducible NO synthase transcripts were studied us-
ing RT-PCR. Secretion of specific IgG antibodies
by splenic cells was investigated.
Survival-based considerations clearly demon-
strate that the A/22-induced protection is Cp-spe-
cific (protection against Loth cannot be induced by
Chlamydia trachomatis nor Chlamydiapneumoniae, and
A/22-treated mice are not protected against the
other intracellular bacteria studied: Listeria monocy-
togenes). Mice are protected against Loth for more
than one year after A/22 immunisation.
Transfer experiments using splenic mononu-
clear cells from protected and unprotected mice
imply that cells responsible for such a protection
are CD4+ T lymphocytes, and that transfer ofserum
from immune mice does not confer any protection
to recipient mice.
Among CD4+ T lymphocytes, two subpopula-
tions exist, Th and Th2 cells, which are defined by
their cytokines synthesis patterns. Cytokine mRNA
synthesis in splenic mononuclear cells, as well as
the isotype of excreted Cp-specific IgG, show that
protected mice exhibit a Thl-type response. This
kind ofimmune response is established by a prefer-
ential production of IFN-y, TNFot, TNF[3 and by
a typical predominance of IgGza among specific IgG
antibodies. It is also characterised by cellular ef-
fector mechanisms.
One of the effector mechanisms involved seems
to be the induced nitric oxide (NO) production in
macrophages during healing ofthe mice. Production
ofmessenger RNA for inducibleNO synthase could
be detected in the peritoneum of A/22-protected
BALB/c mice, as well as in naturally resistant
C57BL/6 mice, after intraperitoneal inoculation
with Loth strain.
This data indicate that Thl-CD4+ T lympho-
cytes and activated macrophages are implicated in
immunity against Cp. Other cellular mechanisms
of bacterial clearance (NK cells or CD8
/ T lympho-
cytes) are probably also involved. This requires fur-
ther studies. Nevertheless, this model of induced
immunoprotection will be a tool to evaluate vaccine
preparations against Chlamydia sp. It will also be
useful to increase our knowledge of the immune
response necessary to cure an acute chlamydial in-
fection.
T-cell mediated immunity against C. pneumoniae
has thus far been studied in persons who have ac-
quired a laboratory infection caused by C. pneumon-
iae strain Kajaani 6.34 A definite antigen-specific
lymphocyte proliferation response, which started to
increase at 3 weeks and had a peak value at 8-9
weeks after the onset of symptoms, was recorded.
T-cell responses to C. pneumoniae antigens are sig-
nificantly stronger in healthy, seropositive individu-
als than in seronegative persons. In contrast to
healthy individuals in whom the T-cell reactivity is
specific to C. pneumoniae antigens, we have recently
observed that patients with severe coronary heart
disease elicit a T-cell response that is cross-reactive
with different chlamydial species and which might
be directed against conserved protein epitopes in
MOMP or even against chlamydial heat shock pro-
teins shared by different chlamydial species. More-
over, high antibody titers to C. pneumoniae in pa-
tients with coronary heart disease were often
associated with a decreased T-cell reactivity against
C. pneumoniae. These preliminary results suggest
that T-cell immunity might be important in the
protection against C. pneumoniae, and that in chronic
infections or in reinfections T-cells may also be
responsible for the immunopathological processes
associated with the disease.
It has been shown that C. pneumoniae is capable
of inducing ILl and TNF production in human
monocytes.
13 We have also shown that in acute C.
pneumoniae pneumonia, triglyceride levels are sig-
nificantly higher and HDL levels, particularly
HDL2, significantly lower than in either viral or
pneumococcal pneumonias. It can be speculated
that in chronic C. pneumoniae infections the continu-
ous production ofTNF might lead to a serum lipid
pattern similar to that which is considered as a risk
factor for coronary heart disease.
Recent data 17 on reinfection in mice indicate that
bacterial cultures are positive only for a couple of
days after the rechallenge. However, the inflamma-
tory changes in the lungs are as strong and long-
lasting and develop earlier than the changes seen
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in primary infection. When convalescent or hyper-
immune serum is given intraperitoneally prior to
the intranasal challenge, Chlamydia cultures stay
negative, but the lung histology shows acute pneu-
monia with polymorphonuclear leukocytes.
The results from animal studies suggest that an-
tibodies, i.e. humoral immunity, may contribute to
protection and that the strong inflammatory re-
sponse seen in the lungs after the rechallenge of
mice with C. pneumoniae may be due to the immu-
nodestructive action of T-cell mediated immunity.
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